Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rilmenidine
- Development stage
- Phase 4
- Lead developer
- Servier
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Rilmenidine is an oxazoline compound and imidazoline analog that functions as a centrally-acting antihypertensive medication. It is primarily used for the treatment of hypertension. Its mechanism of action involves selective binding to I1 imidazoline receptors in the brainstem, which reduces systemic sympathetic tone and peripheral vascular resistance. Rilmenidine also exhibits a mild agonistic effect on alpha-2 adrenergic receptors. This dual action contributes to its blood pressure-lowering effects while offering a favorable side effect profile compared to less selective alpha-2 agonists. The drug is administered orally. Developed by Servier, Rilmenidine is also being investigated for potential benefits in metabolic syndrome, other cardiovascular-related conditions, chronic kidney disease, and longevity research.
- Brand names
- AlbarelHyperiumIteriumTenaxum
- Other names
- oxaminozolinerilmenidenerilmenidine phosphaterilmenidine dihydrogen phosphate
02
Targets
ADRA2A (α2A)I1R (Nischarin)I2R (Imidazoline I2 receptor)mAChR (Muscarinic acetylcholine receptors)Nicotinic Acetylcholine Receptor
Beyond the preview
Go deeper on Rilmenidine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rilmenidine.